Skip to content
PipDig
EUR/USD1.08537 +0.24%GBP/USD1.27311 -0.31%USD/JPY156.835 +0.42%XAU/USD4062.31 +0.67%BTC/USD96403.00 +2.16%

Forex News

Ernexa CEO to Present at H.C. Wainwright Conference

Ernexa Therapeutics CEO Sanjeev Luther will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 12:00 p.m. ET, covering the company's oncology strategy and ERNA-101 progress.

PipDig Newsroom
  • Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 12:00 p.m. ET.
  • The presentation will be held in Kennedy I, 4th Floor.
  • The conference runs September 14–16, 2026, in New York City.
  • Ernexa management will be available for one-on-one meetings with qualified investors during the conference.

Ernexa Therapeutics (Nasdaq: ERNA) CEO Sanjeev Luther will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 12:00 p.m. ET.

Upward view of contemporary laboratory architecture showing curved glass panels and steel framework against a neutral sky.
Ernexa CEO to Present at H.C. Wainwright Conference

The presentation will take place in Kennedy I, 4th Floor. Luther's remarks will give an overview of Ernexa's focused oncology strategy and recent progress with ERNA-101.

Conference Details

The H.C. Wainwright 28th Annual Global Investment Conference runs September 14–16, 2026, in New York City. Ernexa management will be available for one-on-one meetings with qualified investors during the conference.

ERNA-101 and the iMSC Platform

ERNA-101 is Ernexa's lead oncology cell therapy candidate. It is designed to activate and regulate the immune system's response to recognize and attack cancer cells.

Ernexa's initial focus is treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

The company's platform is a differentiated, off-the-shelf-induced mesenchymal stem cell, or iMSC, platform. The core technology involves engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs).

Allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

Company Information

Ernexa Therapeutics is headquartered in Cambridge, Mass..

  • Media contact: Sharon Golubchik.
  • Investor contact: Jenene Thomas, (908) 824-0775.
  • Website: www.ernexatx.com.